Machine learning improves DNA predictions for eye and hair color, but challenges remain for skin tone and facial features.
Finasteride reduces prostate size and PSA levels in young patients.
6 citations
,
August 2005 in “The Journal of Clinical Endocrinology & Metabolism” Finasteride causes temporary cell death in BPH tissues.
1 citations
,
February 2004 in “Dermatologic Surgery” Deep Plane Fixation in scalp surgeries allows for more tissue removal with less tension, leading to better healing and less scarring.
February 2004 in “Dermatologic Surgery” Deep Plane Fixation in scalp surgeries allows for more tissue removal with less tension and minimal scarring.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
164 citations
,
January 2003 in “Drugs” 1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
December 2024 in “PubMed” TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
31 citations
,
January 2008 in “Gynecological endocrinology” Both birth control pills improved hormone levels and skin conditions in women with hyperandrogenism, but the one with drospirenone was more effective.
July 2024 in “Reactions Weekly” 3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
A new lipid-based formula using myristyl myristate can improve estradiol treatment for hair loss.
94 citations
,
August 2002 in “Experimental Dermatology” 17α-estradiol boosts aromatase activity in female hair follicles, potentially helping with hair loss.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
March 2023 in “Reactions Weekly”
May 2021 in “Journal of the Endocrine Society” Transgender females can reach their target estrogen levels using estradiol patches, especially if oral treatments fail or if they're at risk for blood clots. Often, the highest dose patch is needed.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
8 citations
,
April 1991 in “European journal of endocrinology” 3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
October 2012 in “Sax's Dangerous Properties of Industrial Materials”
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
37 citations
,
May 2018 in “Transgender health” Oral estradiol works for many transgender women but needs personalized dosing and monitoring.
17 citations
,
January 2004 in “European journal of obstetrics, gynecology, and reproductive biology/European journal of obstetrics & gynecology and reproductive biology” Certain hormone medications can treat symptoms like acne and unwanted hair, regulate periods, and prevent pregnancy in women and teenage girls.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
3 citations
,
January 1992 in “Gynecological Endocrinology” 3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.